Literature DB >> 7524282

The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets.

D D Taub1, A R Lloyd, J M Wang, J J Oppenheim, D J Kelvin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7524282     DOI： 10.1007/978-1-4615-2952-1_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  8 in total

1.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

Review 2.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres.

Authors:  Yana Wang; Darrell J Irvine
Journal:  Biomaterials       Date:  2011-04-03       Impact factor: 12.479

4.  Antitumor activity mediated by CpG: the route of administration is critical.

Authors:  Yanyan Lou; Chengwen Liu; Gregory Lizée; Weiyi Peng; Chunyu Xu; Yang Ye; Brian A Rabinovich; Yared Hailemichael; Alexander Gelbard; Dapeng Zhou; Willem W Overwijk; Patrick Hwu
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

5.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

6.  Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Authors:  Diana M Brainard; William G Tharp; Elva Granado; Nicholas Miller; Alicja K Trocha; Xiang-Hui Ren; Brian Conrad; Ernest F Terwilliger; Richard Wyatt; Bruce D Walker; Mark C Poznansky
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  On the inflammatory response in metal-on-metal implants.

Authors:  Ulrike Dapunt; Thomas Giese; Felix Lasitschka; Jörn Reinders; Burkhard Lehner; Jan Philippe Kretzer; Volker Ewerbeck; Gertrud Maria Hänsch
Journal:  J Transl Med       Date:  2014-03-21       Impact factor: 5.531

8.  Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.

Authors:  Natalia Teleshova; Marla J Keller; José A Fernández Romero; Barbara A Friedland; George W Creasy; Marlena G Plagianos; Laurie Ray; Patrick Barnable; Larisa Kizima; Aixa Rodriguez; Nadjet Cornejal; Claudia Melo; Gearoff Cruz Rodriguez; Sampurna Mukhopadhyay; Giulia Calenda; Shweta U Sinkar; Thierry Bonnaire; Asa Wesenberg; Shimin Zhang; Kyle Kleinbeck; Kenneth Palmer; Mohcine Alami; Barry R O'Keefe; Patrick Gillevet; Hong Hur; Yupu Liang; Gabriela Santone; Raina N Fichorova; Tamara Kalir; Thomas M Zydowsky
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.